-
Annual Review | Professor Wei Xu: New Trends and Future Directions in the Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL)
From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. During the meeting, Professor Wei Xu from Jiangsu Provincial People’s Hospital provided a comprehensive review of key advances in CLL treatment, therapeutic decision-making in high-risk disease, and future research directions,…
-
Yixian Breast Cancer Conference 2025 | Professor Chang Gong: Stratified Optimization and Precision Escalation/De-Escalation in HER2-Positive Breast Cancer
HER2-positive breast cancer was once associated with aggressive behavior and poor prognosis. However, with the rapid advancement of targeted therapies—particularly antibody–drug conjugates (ADCs)—this subtype has evolved into a highly treatable and potentially curable disease. In 2025, landmark studies across neoadjuvant, adjuvant, and metastatic settings have reshaped treatment paradigms toward greater precision and individualization. During the…
-
2025 Yixian Breast Cancer Conference | Professor Kun Wang: Immunotherapy, Chemotherapy, and ADCs Advancing in Parallel to Drive Continued Breakthroughs in Triple-Negative Breast Cancer Outcomes
The 2025 Yixian Breast Cancer Conference, held alongside the 2025 CSCO Breast Cancer Southern Forum, the Second Chinese Young Breast Cancer Consensus Conference, and the Fourth Yixian Breast Cancer Nursing Conference, took place in Guangzhou on December 26–27, 2025. The meeting focused on standardization of breast cancer care, emerging therapeutic strategies, and precision management in…
-
Northern Breast Cancer Forum 2026 | Professor Peng Yuan: Driving Clinical Transformation Through “Three New Forces” and Anticipating Key Updates in the 2026 CSCO Breast Cancer Guidelines
As China’s flagship academic event in breast cancer at the start of each year, the Northern Breast Cancer Forum continues to bridge global scientific advances with localized clinical practice. From the SERENA-6 trial, which pioneers molecular monitoring for endocrine resistance, to the rapid rise of Trop-2–targeted ADCs and expanded access to PI3K/AKT/mTOR pathway inhibitors under…
-
Professor Yongsheng Wang: What Has Changed—and What Remains—in Breast Cancer Surgery?
Breast cancer has recently surpassed lung cancer as the most commonly diagnosed cancer among women worldwide. The status of regional lymph node involvement remains a key prognostic factor, directly influencing disease staging, treatment planning, and survival outcomes. While axillary lymph node dissection (ALND) has long been the standard for staging, it carries substantial morbidity. As…
-
2026 CASH | Science Knows No Borders, Cooperation Shapes the Future: A Dialogue with International Forum Chair Professor Toshio Suda
As a new year begins, global leaders in hematology gathered in Tianjin from January 9–11, 2026, for the 6th China Hematology Discipline Development Conference (CASH). This year’s congress introduced its first-ever International Forum, establishing a new bridge for in-depth dialogue between Chinese and global hematology communities. As one of the Forum Chairs, Professor Toshio Suda…
-
Lymphoma Frontline Advances | Professor Qingqing Cai: Breakthrough Progress in First-Line Bispecific Antibody Therapy for Lymphoma — ASH 2025 Special
The 2025 American Society of Hematology (ASH) Annual Meeting recently concluded in Orlando, USA, showcasing major breakthroughs in lymphoma research and offering new directions for optimizing clinical care. To translate cutting-edge science into clinical insight, Oncology Frontier – Hematology Frontier partners with Professor Qingqing Cai of Sun Yat-sen University Cancer Center to present the “Lymphoma…
Connecting Medical Expertise through Media
